Covaxin 65.2 percent effective against Delta variant

Bharat Biotech’s Covaxin has demonstrated 77.8 percent effectiveness against symptomatic COVID-19 and65.2 percent protection against the new Delta variant.

The company on Saturday said it concluded the final analysis of Covaxin efficacy from Phase3 trials.

The efficacy analysis demonstrates Covaxin to be 93.4 percent effective against severe symptomatic COVID-19 cases while safety analysis shows adverse events reported were similar to placebo, with 12 percent of subjects experiencing commonly known side effects and less than 0.5 percent feeling serious adverse events.

The efficacy data demonstrates 63.6 percent protection against asymptomatic COVID-19, a release from the city-based vaccine maker said.

Phase 3 clinical trials of the vaccine was an event-driven analysis of 130 symptomatic COVID-19 cases, reported at least two weeks after the second dose, conducted at 25 sites across India.

0

0